Related references
Note: Only part of the references are listed.MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Michael Weller et al.
NATURE REVIEWS NEUROLOGY (2010)
Relative Cerebral Blood Volume Values to Differentiate High-Grade Glioma Recurrence from Posttreatment Radiation Effect: Direct Correlation between Image-Guided Tissue Histopathology and Localized Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging Measurements
L. S. Hu et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2009)
Population-Based Study of Pseudoprogression after Chemoradiotherapy in GBM
Gloria B. Roldan et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2009)
Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging
Jennifer L. Clarke et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2009)
New advances that enable identification of glioblastoma recurrence
Isaac Yang et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide
Walter Taal et al.
CANCER (2008)
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
Alba A. Brandes et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) robustly detects and distinguishes 11p15 abnormalities associated with overgrowth and growth retardation
R. H. Scott et al.
JOURNAL OF MEDICAL GENETICS (2008)
Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas
Eva M. Grasbon-Frodl et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas
Judith Wm Jeuken et al.
LABORATORY INVESTIGATION (2007)
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide
Olivier L. Chinot et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment
Daniel P. Cahill et al.
CLINICAL CANCER RESEARCH (2007)
Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma
Jill A. Maxwell et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Multiplex ligation-dependent probe amplification - A diagnostic tool for simultaneous identification of different genetic markers in glial tumors
Judith Jeuken et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2006)
Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas
M Brell et al.
CLINICAL CANCER RESEARCH (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences
AOH Nygren et al.
NUCLEIC ACIDS RESEARCH (2005)
Immunohistochemical study for O6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas
S Nakasu et al.
JOURNAL OF NEURO-ONCOLOGY (2004)
Share Paper
